Overview

Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor

Status:
NOT_YET_RECRUITING

Trial end date:
2034-06-01

Target enrollment:

Participant gender:

Summary

This is a prospective, randomized, open-label, multicenter phase III study to explore chemotherapy omission in hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with lymph node negative disease receiving adjuvant endocrine therapy and cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor.

Phase:

PHASE3

Details

Lead Sponsor:

Fudan University

Treatments:

Aromatase Inhibitors
Chemotherapy, Adjuvant
Cyclophosphamide
Docetaxel